At the time of writing, ARS Pharmaceuticals Inc [SPRY] stock is trading at $17.49, up 2.64%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SPRY shares have gain 15.07% over the last week, with a monthly amount glided 20.45%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Raymond James upgraded its rating to Strong Buy on August 13, 2024, and elevated its price target to $22. On August 12, 2024, Leerink Partners reiterated its Outperform rating and revised its price target to $20 on the stock. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $18 on July 25, 2024. Leerink Partners upgraded its rating to a Outperform and raised its price target to $18 on March 05, 2024. William Blair upgraded its rating to Outperform for this stock on February 20, 2024. In a note dated September 20, 2023, William Blair downgraded an Mkt Perform rating on this stock.
For the past year, the stock price of ARS Pharmaceuticals Inc fluctuated between $3.38 and $17.08. Currently, Wall Street analysts expect the stock to reach $23.33 within the next 12 months. ARS Pharmaceuticals Inc [NASDAQ: SPRY] shares were valued at $17.49 at the most recent close of the market. An investor can expect a potential return of 33.39% based on the average SPRY price forecast.
Analyzing the SPRY fundamentals
According to ARS Pharmaceuticals Inc [NASDAQ:SPRY], the company’s sales were 0.50M for trailing twelve months, which represents an 4900.00% jump. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -120.71%, Pretax Profit Margin comes in at -95.37%, and Net Profit Margin reading is -95.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.2 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.75 points at the first support level, and at 16.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.37, and for the 2nd resistance point, it is at 19.25.
Ratios To Look Out For
It is important to note that ARS Pharmaceuticals Inc [NASDAQ:SPRY] has a current ratio of 32.78. As well, the Quick Ratio is 32.78, while the Cash Ratio is 5.45. Considering the valuation of this stock, the price to sales ratio is 3580.12, the price to book ratio is 7.88.
Transactions by insiders
Recent insider trading involved Scott Kathleen D., Chief Financial Officer, that happened on Oct 16 ’24 when 12500.0 shares were sold. CHIEF MEDICAL OFFICER, Tanimoto Sarina completed a deal on Oct 15 ’24 to sell 100000.0 shares. Meanwhile, PRESIDENT AND CEO Lowenthal Richard E sold 100000.0 shares on Oct 15 ’24.
